Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Shareholder Meeting (November 2022)
26 slides from Arovella Therapeutics's shareholder meeting presentation, Nov 17, 2022
Slide 1: Annual General Meeting November 2022
For personal use only ASX: ALA ANNUAL GENERAL MEETING November 2022
Slide 2: Arovella Board of Directors
Arovella Board of Directors Dr. Liz Stoner Dr. Michael Baker Dr. Debora Barton For personal use only INTERIM CHAIRPERON CEO & MANAGING DIRECTOR DIRECTOR Dr. Stoner is a distinguished Over 15 years experience in scientific Dr. Barton has over 20 years of oncology biopharma executive, who brings decad
Slide 3: Recent Milestones
Recent Milestones Commenced CAR19 Plasmid and Plasmid and Lentivirus Vector Manufacturing For personal use only manufacturer selected JAN 2022 DEC 2021 Appointed Dr Mini Bharathan – VP Arovella selected to present at Development and Translational Biotech Showcase Medicine DEC 2021 JAN 2022 Q-Gen sel
Slide 4: Arovella Company Overview
Arovella Company Overview Financial Snapshot ALA Price and Volume - 12 Months1 ASX CODE ALA For personal use only 35000000 0.07 Market capitalisation1 $16.7 million 30000000 Shares on issue 669.8 million 0.06 52-week low / high $0.020 / $0.057 25000000 0.05 Cash (Sep 30 2022)2 $5.3 million 20000000
Slide 5: Biotech Sector Global Performance
Biotech Sector Global Performance As of October 2022, global biotech enterprise values were down 68% since the 2021 peak and down 45% year to date1 For personal use only In October 2022, 228 Life Science companies were trading at negative enterprise values 1 Total Enterprise Value of Publicly Tr
Slide 6: Cancer Continues to be a Major Health Issue
Cancer Continues to be a Major Health Issue For personal use only Worldwide, an estimated Cancer is a leading The global cancer 19.3 million new cancer cause of death therapeutics market is cases (18.1 million worldwide, accounting expected to reach $366 excluding non-melanoma for nearly 10 million
Slide 7: Cell Therapy Revolution to Treat Cancer
Cell Therapy Revolution to Treat Cancer Recent Media Attention – Feb & May 2022 For personal use only 7 © Copyright Arovella Therapeutics Ltd 2022
Slide 8: iNKT Cell Therapy Platform
iNKT Cell Therapy Platform For personal use only © Copyright Arovella Therapeutics Ltd 2022
Slide 9: CAR-iNKT Cell Therapy Production and Advantages
CAR-iNKT Cell Therapy Production and Advantages Manufacturing For personal use only Collect Healthy Isolate iNKT cells Reprogram iNKT cells to Expand CAR-iNKT cells to Vial and freeze Donor Blood produce a CAR grow billions of cells CAR-iNKT cells Dosing Thaw CAR-iNKT cells Allogenic Manufacturing A
Slide 10: CAR-iNKT Cells are Engineered to Enhance Activity
CAR-iNKT Cells are Engineered to Enhance Activity APPROVED CAR-NK CELLS CAR-iNKT For personal use only CAR-T CELLS CELLS Subpopulation of T cells with NK cell properties Intrinsic anti-cancer receptor (dual targeting) Naturally suppress GVHD Allogeneic, ‘off-the-shelf’ dosing
Slide 11: Arovella Therapeutics Pipeline
Arovella Therapeutics Pipeline Cell Therapy For personal use only INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE2/31 PARTNER ALA-101 CD19 expressing CD19 Expressing Lymphoma (CAR19-iNKT) cancers ALA-101 + Solid tumours Solid Tumours CF33-CD19 ALA-104 Multiple Multiple Myeloma & Solid Tumours (DKK1-C
Slide 12: CAR19-iNKT (ALA-101)
For personal use only CAR19-iNKT (ALA-101) An off-the-shelf cell therapy for CD19 expressing cancers © Copyright Arovella Therapeutics Ltd 2022
Slide 13: ALA-101: CAR19-iNKT Cells to Treat Blood Cancers
ALA-101: CAR19-iNKT Cells to Treat Blood Cancers CAR19-iNKT Outperforms Conventional Therapies For personal use only ALA-101 is anticipated to be an effective, Faster Killing of Cancer Spontaneous Secondary off-the-shelf cell therapy for the Cells That Have CD1d Remission treatment of CD19 express
Slide 14: DKK1-CAR-iNKT (ALA-104)
For personal use only DKK1-CAR-iNKT (ALA-104) An off-the-shelf cell therapy for multiple myeloma (blood cancer) and potentially solid tumours © Copyright Arovella Therapeutics Ltd 2022
Slide 15: DKK1-CAR-T Cell Activity in Multiple Myeloma
DKK1-CAR-T Cell Activity in Multiple Myeloma DKK1-CAR-T cells were tested in three different animal models for multiple myeloma, displaying robust activity in For personal use only all standard models Model 1 – U266 Model 2 – KMS-12-BM Model 3 – MM.1S 100 100 100 S u r v iv a l p e r c e n ta g e S
Slide 16: Potential Application of ALA-104
Potential Application of ALA-104 For personal use only DKK1-CAR-T cells display robust activity in animal models against multiple myeloma, lung cancer, pancreatic cancer and triple negative breast cancer Once we generate DKK1-CAR-iNKT cells, we will test them against blood cancers and solid tumo
Slide 17: CF33-CD19 + CAR19-iNKT
For personal use only CF33-CD19 + CAR19-iNKT An off-the-shelf cell therapy and oncolytic virus combination to mark and destroy solid tumours © Copyright Arovella Therapeutics Ltd 2022
Slide 18: Combining CAR19-iNKT and CF33-CD19 (onCARlytics)
Combining CAR19-iNKT and CF33-CD19 (onCARlytics) CF33 is an oncolytic virus that targets tumour CAR19-iNKT cells are very potent and are For personal use only cells and not healthy cells rapidly activated to kill CD19 expressing The virus was developed at City of Hope by cancer cells Professor
Slide 19: What is the Mechanism of Action?
What is the Mechanism of Action? For personal use only 19 © Copyright Arovella Therapeutics Ltd 2022
Slide 20: Expanding ALA-101's Utility
Expanding ALA-101’s Utility For personal use only We expect CAR19-iNKT cells to be effective against blood cancers that naturally produce CD19 Combining CF33-CD19 with CAR19- iNKT cells opens up the possibility of treating a range of solid tumours 20 © Copyright Arovella Therapeutics Ltd 2022
Slide 21: Upcoming Milestones FY23
Upcoming Milestones FY23 Activity for Arovella (now to June 2023) Therapy Complete (CY) For personal use only Strategic planning outcomes Company Wide Completed Complete process development and confirmation manufacturing runs for ALA-101 Q2 2023 CAR19-iNKT Finalise CAR19-iNKT and onCARlytics A
Slide 22: Arovella's Potential Cancer Targets
Arovella’s Potential Cancer Targets ALA-101 For personal use only ALA-101 + CF33-CD19 ALA-104 Non- Head and Prostate Brain Triple Pancreatic Lung Cancer8 Multiple Hodgkin’s Neck Cancer2 Cancer3 Metastases4,5 Negative Cancer7 Myeloma9 Lymphoma1 Breast Cancer6 80,470 cases 66,470 cases 268,490 cases 1
Slide 23: Arovella Therapeutics Summary
Arovella Therapeutics Summary For personal use only World Leading Partners Allogeneic Platform, Two Targets Acquiring New Technologies Arovella licenced its iNKT Cell Therapy Arovella is developing off the shelf cell Arovella continues to focus on sourcing, Platform from Imperial College London and
Slide 24: Thank You
For personal use only Thank You Dr. Michael Baker CEO & Managing Director Email: mbaker@arovella.com Mobile: +61 403 468 187 © Copyright Arovella Therapeutics Ltd 2022
Slide 25: Committed to helping people live longer and healthier lives
For personal use only Committed to helping people live longer and healthier lives Patient-Centric It starts with the end in mind. In our case, it is our patients. At Arovella, we are invested in making a positive difference in helping patients live longer and healthier lives. Creating a brighter fut
Slide 26: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). For pers
Arovella Therapeutics — Shareholder Meeting (November 2022) on 6ix